BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

993 related articles for article (PubMed ID: 10553155)

  • 41. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.
    Riccioni R; Saulle E; Militi S; Sposi NM; Gualtiero M; Mauro N; Mancini M; Diverio D; Lo Coco F; Peschle C; Testa U
    Leukemia; 2003 Jan; 17(1):98-113. PubMed ID: 12529666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
    Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
    Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Detection of PML/RARa transcripts in acute promyelocytic leukemia by real-time quantitative reverse transcription polymerase chain reaction].
    Lang L; Li HM; Liu H; Wang YM; Zhang XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):714-9. PubMed ID: 17708789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Problems existing in differentiation therapy of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA).
    Wang ZY; Chen Z; Huang W; Li XS; Lu JX; Huang LA; Zhang FQ; Gu LJ; Ouyang RR; Chen SJ
    Blood Cells; 1993; 19(3):633-41; discussion 642-7. PubMed ID: 8018944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
    Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocal PML/RARA or RARA/PML fusion genes.
    Mozziconacci MJ; Liberatore C; Brunel V; Grignani F; Arnoulet C; Ferrucci PF; Fernandez F; Sainty D; Pelicci PG; Birg F; Lafage-Pochitaloff M
    Genes Chromosomes Cancer; 1998 Jul; 22(3):241-50. PubMed ID: 9624536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
    Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Curing APL through PML/RARA degradation by As2O3.
    Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
    Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho).
    Fukutani H; Naoe T; Ohno R; Yoshida H; Miyawaki S; Shimazaki C; Miyake T; Nakayama Y; Kobayashi H; Goto S
    Leukemia; 1995 Sep; 9(9):1478-82. PubMed ID: 7658715
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.
    Martinelli G; Ottaviani E; Testoni N; Visani G; Diverio D; D'Elia G; Mandelli F; Tura S
    Haematologica; 1998 Nov; 83(11):985-8. PubMed ID: 9864917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia.
    Takayama N; Kizaki M; Hida T; Kinjo K; Ikeda Y
    Exp Hematol; 2001 Jul; 29(7):864-72. PubMed ID: 11438209
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia.
    Diverio D; Riccioni R; Pistilli A; Buffolino S; Avvisati G; Mandelli F; Lo Coco F
    Leukemia; 1996 Jul; 10(7):1214-6. PubMed ID: 8684004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Retinoic acid receptor alpha gene in t (15; 17) APL].
    Takashima T; Misawa S
    Nihon Rinsho; 1992 Jun; 50(6):1363-8. PubMed ID: 1325570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
    Chen SJ; Chen LJ; Zhou GB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
    Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
    Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
    Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.
    Tarkanyi I; Dudognon C; Hillion J; Pendino F; Lanotte M; Aradi J; Ségal-Bendirdjian E
    Leukemia; 2005 Oct; 19(10):1806-11. PubMed ID: 16107885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.